Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Atro Medical Bv |
| Country | Netherlands |
| Start Date | Apr 01, 2023 |
| End Date | Sep 30, 2025 |
| Duration | 913 days |
| Number of Grantees | 1 |
| Roles | Coordinator |
| Data Source | European Commission |
| Grant ID | 190115658 |
ATRO Medical developed a revolutionary prothesis that quickly relieves pain and restores mobility for severe KOA patients with a dysfunctional lateral meniscus: Trammpolin.
We offer a minimally invasive, low impact procedure that postpones undesirable TKR and reduces KOA-related healthcare costs and medication dependency, while restoring full knee functioning.
Our innovation is composed of a dual highly biocompatible polymer that carries the body weight and is uniquely shaped to reproduce the anatomical shape and mechanical properties of the native meniscus.
The technology has proven itself for the medial meniscus and received the Breakthrough Device Designation of the US FDA in 2020.
For successful market entry of our lateral Trammpolin in 2026, we aim to finalize our pre-clinical activities, conduct a FIH-study, and obtain CE-marking.
In parallel we will perform a health economics analysis as a crucial step towards obtaining reimbursement for large scale uptake in the medical system.
Atro Medical Bv
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant